SESSION TITLE: Medical Student/Resident Lung Cancer Posters SESSION TYPE: Med Student/Res Case Rep Postr PRESENTED ON: October 18-21, 2020 INTRODUCTION: Everolimus, an oral inhibitor of mTOR, is a targeted anti-neoplastic therapy for advanced NSCLC. We present a case of non-infectious pneumonitis (NIP) in a patient being treated with everolimus. Prompt recognition and management is essential. CASE PRESENTATION: 64-year-old male with Stage IV NSCLC, recently started on 6th line salvage therapy with everolimus, presented with 4 days of dyspnea, fatigue, intermittent chills, productive cough, and scant hemoptysis. On arrival, patient was afebrile, tachycardiac and hypoxic to 88% on room air. He was found to have mild anemia and elevated LDH without leukocytosis or thrombocytopenia. CT chest showed increase in RUL perihilar mass and new peribronchovascular airspace disease in all lobes. Differential diagnosis included infectious and noninfectious findings of new airspace disease. Everolimus was discontinued and patient was started on oxygen supplementation to maintain oxygen saturation >88%, along with 60 mg IV solumedrol q24 hours, broad-spectrum antibiotic coverage with piperacillin-tazobactam, linezolid, and azithromycin. Bronchoalveolar lavage (BAL) was negative for mycobacterium, fungal or bacterial pathogens. Patient improved symptomatically after starting steroids along with reduction in oxygen requirement. DISCUSSION: Everolimus is used in select cases of advanced NSCLC. NIP is a potentially fatal adverse effect of mTOR inhibitors, more frequently seen in NSCLC as compared to other solid malignancies and in patients with baseline interstitial lung disease. Severe or life-threatening symptoms requiring discontinuation of therapy, as seen in our patient, are uncommon and require prompt diagnosis and treatment. Common presentation includes cough, dyspnea, and hypoxemia. Hemoptysis, as seen in our patient, is rare. Radiographic changes in everolimus associated NIP include, lower lobe predominant ground-glass and reticular opacities, focal parenchymal consolidations, and rarely, pleural effusions. Pulmonary function tests can show a restrictive pattern or abnormally low DLCO. Histological testing including BAL, lung biopsy, and sputum cultures help exclude infection, granulomatous disease or malignancy. Management is guided by grade of pneumonitis, and includes close clinical observation, dose reduction or discontinuation. Systemic steroids can be given to patients with grade ≥2 pneumonitis until symptoms improve to grade ≤1. CONCLUSIONS: Patients on everolimus therapy for advanced NSCLC are at high risk of developing NIP, that can sometimes lead to life-threatening hypoxic respiratory failure. Urgent diagnosis and guideline directed management of this adverse effect is highly important. Reference #1: Alvarez RH, Bechara RI, Naughton MJ, Adachi JA, Reuben JM. Emerging Perspectives on mTOR Inhibitor-Associated Pneumonitis in Breast Cancer. Oncologist. 2018;23(6):660-669. Reference #2: Grünwald V, Weikert S, Pavel M, et al. Practical Management of Everolimus-Related Toxicities in Patients with Advanced Solid Tumors. Onkologie. 2013;36:295-302. Reference #3: White DA, Schwartz LH, Dimitrijevic S, Scala LD, Hayes W, Gross SH. Characterization of Pneumonitis in Patients with Advanced Non-small Cell Lung Cancer Treated with Everolimus (RAD001). Journal of Thoracic Oncology. 2009;4(11):1357-1363. DISCLOSURES: No relevant relationships by zainub ajmal, source=Web Response No relevant relationships by Sana Ghalib, source=Web Response No relevant relationships by Boris Shkolnik, source=Web Response No relevant relationships by Fatima Tuz Zahra, source=Web Response